Cambridge Innovation Capital is an established VC firm embedded in the UK technology ecosystem with privileged access to the University of Cambridge. The firm manages over £600m of capital and invests across deep tech and life sciences.
Victor brings venture investment experience in deep tech, life sciences, and plant sciences, alongside background as an exited founder. He currently serves as chairperson at St John's Innovation Centre and holds leadership roles across several investment firms.
Andrew brings venture capital and investment experience from Cambridge Innovation Capital, True North Venture Partners, and MalibuIQ. He also serves on the board of the British Private Equity and Venture Capital Association.
Michael is a partner at Cambridge Innovation Capital and serves on the board of several life sciences and technology companies, including Congenica and Epitopea.
Carol brings venture capital experience from roles at Cocoon Capital and Cambridge Innovation Capital, alongside directorships at Culmen House and Spectrum Capital Management.
Vin brings venture capital and entrepreneurial experience across artificial intelligence infrastructure and cybersecurity, having previously served as a partner at Cambridge Innovation Capital and founded several ventures.
Robert brings life sciences investment and biotech executive experience, holding roles including venture partner at Cambridge Innovation Capital and chief medical officer at Microbiotica. He also serves on the boards of Sortera Bio and Pretzel Therapeutics.
The company completed an $18.5m total Seed round with backing from Cambridge Innovation Capital, UP.Partners, Insight Partners, and InMotion Ventures.
"Engineering teams require ever-faster, more flexible simulation, but do not have the technology to deliver on these demands. Generative physics introduces a fundamentally new approach to engineering, unlocking innovation across fields ranging from aerospace and automotive to data-centre design. We now have the capital and investor support to accelerate our research roadmap and scale commercial adoption. This could be the ChatGPT moment for physics."
BGF and Tencent join existing shareholders to support the biotechnology company in advancing its drug development programmes.
"We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support."
The Series C round was led by a strategic investor and backed by existing supporters to drive international expansion.
"We are delighted to continue backing the ambitious CGD team in bringing groundbreaking GaN technologies to market. As we strive towards a low-carbon future, CGD’s products can deliver higher performance while enabling up to 50% energy savings across multiple growing sectors such as automotive, renewable energy, and data centres. We look forward to seeing the impact that CGD can make in enabling greener power electronics"
The Cambridge semiconductor startup secured backing from Octopus Ventures, Cambridge Innovation Capital, BGF, and Foresight Group.
"Securing this Series A funding underscores the strong confidence our investors have in ForeFront RF’s vision and market potential. With continued support from Foresight Group and BGF, and new partnerships with Octopus Ventures and Cambridge Innovation Capital, we’re well-positioned to scale rapidly from engineering prototypes to mass production."
The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.
"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."
